Amgen’s Imdelltra (tarlatamab) plus AstraZeneca’s Imfinzi (durvalumab) met the primary overall survival endpoint in a Phase III frontline maintenance trial in extensive-stage small-cell lung cancer (ES-SCLC), according to the study’s primary readout. The result adds a potentially practice-changing option for post-induction maintenance. In parallel, analysts framed Bristol Myers Squibb’s arlo-cel as better positioned for a more heavily treated multiple myeloma subgroup after QUINTESSENTIAL Phase 2 results. Together, the updates show continued momentum in differentiation strategies for difficult-to-treat solid tumors and late-line blood cancers.